Physician profile
James Jones
NPI 1770577561
$2,452.87
in general payments reported to CMS, 2019-2025
20 companies · $88.55 in 2025
The $88.55 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $280 · 2021: $436 · 2022: $429 · 2023: $383 · 2024: $271 · 2025: $88.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.63 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,252.75 | 2019-2025 | Trelegy Ellipta, Nucala |
| Insmed, INC. | $191.58 | 2019-2024 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $177.05 | 2019-2023 | Uptravi |
| Grifols USA, LLC | $116.36 | 2021-2024 | Prolastin-C Liquid |
| Inari Medical, INC. | $101.71 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mylan Specialty L.P. | $99.39 | 2021-2024 | Yupelri |
| Genentech USA, INC. | $94.95 | 2019-2023 | Xolair |
| Abbvie INC. | $88.39 | 2022-2025 | |
| Ambu INC. | $51.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.11 | 2023 | Zerbaxa |
| Philips North America LLC | $28.40 | 2020 | |
| Gilead Sciences, INC. | $28.20 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $24.74 | 2019-2020 | |
| United Therapeutics Corporation | $22.76 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.92 | 2025 | Myfembree |
| Boston Scientific Corporation | $16.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.75 | 2021 | |
| Genzyme Corporation | $14.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.